In vivo, CRT silencing inhibited subcutaneous tumor growth and liver metastasis of pancreatic tumor, which was consistent with the studies in gastric and bladder cancers.7, 49 Moreover, consistent with the results in vitro, CRT silencing significantly inhibited Fibronectin, Integrinβ1, c-Myc and pERK and upregulated E-cad protein expression in vivo, which was also observed in clinical tissues. The gene discussed is EIF2AK3; the disease is urinary bladder carcinoma.